Protein Z Circulates in Plasma in a Complex with Protein Z-Dependent Protease Inhibitor

Summary

Protein Z (PZ) is a vitamin K-dependent plasma protein that forms a Ca⁺⁺-dependent complex with factor Xa at phospholipid surfaces. This interaction between PZ and factor Xa enhances by >1000-fold the inhibition of factor Xa by the serpin called protein Z-dependent protease inhibitor (ZPI). These experiments show that PZ also binds ZPI in a process that does not require Ca⁺⁺ or phospholipids. In pooled normal plasma, which contains excess ZPI relative to PZ, all the PZ appears to be bound in a complex with ZPI. The binding of PZ to ZPI reduces the rate and extent of factor XIa inhibition produced by ZPI. During the course of these studies, it was noted that a PZ purification procedure, that included NaSCN (2.0 M) elution of PZ from an immunoaffinity column, produced aggregated, inactive forms of PZ.

Keywords

Protein Z - protein Z-dependent protease inhibitor - factor Xa - factor XIa

• References

• 1 Prowse CV, Esnouf PM. The isolation of a new warfarin-sensitive protein from bovine plasma. Biochem Soc Trans 1977; 5: 255-6.
• 2 Broze G, Miletich J. Human Protein Z. J Clin Invest 1984; 73: 933-8.
• 3 Fujimaki K, Yamazaki T, Taniwaki M, Ichinose A. The gene for human protein Z is localized to chromosome 13 at band q34 and is coded by eight regular exons and one alternative exon. Biochemistry 1998; 37: 6838-46.
• 4 Højrup P, Jensen M, Petersen T. amino acid sequence of bovine protein Z: a vitamin K-dependent serine protease homolog. FEBS 1985; 184: 333-8.
• 5 Sejima H, Hayashi T, Deyashiki Y, Nishioka J, Suzuki K. Primary structure of vitamin K-dependent human protein Z. Biochem Biophys Res Comm 1991; 171: 661-8.
• 6 Ichinose A, Takeya H, Espling E, Iwanaga S, Kisiel W, Davie EW. Amino acid sequence of human protein Z, a vitamin K-dependent plasma glycoprotein. Biochem Biophys Res Comm 1990; 172: 1139-44.
• 7 Miletich J, Broze G. Human plasma protein Z antigen: range in normal subjects and effect of warfarin therapy. Blood 1987; 69: 1580-6.
• 8 Hogg P, Stenflo J. Interaction of vitamin K-dependent protein Z with thrombin. J Biol Chem 1990; 266: 10953-8.
• 9 Hogg PJ, Stenflo J. Interaction of human protein Z with thrombin: Evaluation of the species difference in the interaction between bovine and human protein Z and thrombin. Biochem. Biophys. Res. Commun. 1991; 178: 801-7.
• 10 Morita T, Kaetsu H, Mizuguchi J, Kawabata S, Iwanaga S. A characteristic property of vitamin K-dependent plasma protein Z. J Biochem 1988; 104: 368-74.
• 11 Kemkes-Matthes B, Matthes KJ. Protein Z deficiency: A new cause of bleeding tendency. Thromb Res 1995; 79: 49-55.
• 12 Greten J, Kemkes-Mathes B, Nawroth PP. Prothrombin complex concentrate contains Protein Z and prevents bleeding in a patient with protein Z deficiency. Thromb Haemost 1995; 74: 992-3.
• 13 Kemkes-Matthes B. Protein Z. Biomedical Progress 2000; 13: 51-4.
• 14 Subramaniasivam R, Mauron T, Lammle B, Wuillemin WA. Protein Z in healthy individuals and in patients with a bleeding tendency. 1998 102. 1219-23.
• 15 Gamba G, Bertolino G, Montani N, Spedini P, Balduini CL. Bleeding tendency of unknown origin and protein Z levels. Thromb Res 1998; 90: 291-5.
• 16 Yin Z-F, Huang Z-F, Cui J, Fiehler R, Lasky N, Ginsburg D, Broze G. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci 2000; 97: 6734-8.
• 17 Han X, Fiehler R, Broze G. Isolation of a protein Z-dependent protease inhibitor. Proc Natl Acad Sci 1998; 95: 9250-5.
• 18 Han X, Fiehler R, Huang Z-F, Broze G. The protein Z-dependent protease inhibitor is a serpin. Biochemistry 1999; 38: 11073-8.
• 19 Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Science 1995; 4: 2411-23.
• 20 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
• 21 Current Protocols in Molecular Biology. Vol. 2 Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, and Struhl K. eds. New York: John Wiley and Sons; 1989: 10.2.1-10.2.6.
• 22 Han X, Fiehler R, Broze Jr GJ. Characterization of protein Z-dependent protease inhibitor. Blood 2000; 96: 3049-55.
• 23 Tabatabai A, Fiehler R, Broze G. Oxidation of protein Z blocks its interaction with protein Z-dependent protease inhibitor [(abstract]. Blood 1999; 94: 457a.
• 24 Levine RL, Mosoni L, Berlett BS, Stadtman ER. Methionine residues as endogenous antioxidants in proteins. Proc Natl Acad Sci USA 1996; 93: 15036-40.
• 25 Rezaie AR, Copper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 1995; 270: 25336-9.
• 26 Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H. Alteration of serpin specificity by a protein cofactor: vitronectin endows plasminogen activator 1 with thrombin inhibitory properties. J Biol Chem 1990; 265: 13029-35.
• 27 Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood 1991; 78: 1254-61.
• 28 Naski MC, Lawrence DA, Moshert DF, Podor TJ, Ginsburg D. Kinetics of inactivation of α-thrombin by plasminogen activator inhibitor-1: comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem 1993; 268: 12367-72.
• 29 Fa M, Karolin J, Aleshkov S, Strandberg L, Johansson LB-A, Ny T. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin. Biochemistry 1995; 34: 13833-40.
• 30 van Meijer M, Smilde A, Tans G, Nesheim ME, Pannekoek H, Horrevoets AJG. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. Blood 1997; 901874-82.
• 31 van Meijer M, Stoop A, Smilde A, Preissner KT, van Zonneveld A-J, Pannekoek H. The composition of complexes between plasminogen activator inhibitor 1, vitronectin, and either thrombin or tissue-type plasminogen activator. Thromb Haemost 1997; 77: 516-21.